The clinical path describes what every patient travels. This page describes what sits beyond it: the tier of advanced diagnostics and interventions that a few people reach, after the baseline, once their biology and their situation actually call for it. The point of mapping it openly is not to advertise it — it is to be honest that the frontier exists, to show by what principle one is admitted to it, and to label every part of it for what it really is. A map with a gate and honest labels, not a menu.
The single most important thing to understand about this layer is what the source material states plainly: advanced interventions are not automatically available after intake. They are considered only after diagnostic review, risk stratification, physician approval and compliance review. The layer sorts into tiers — core foundational work, advanced-optional diagnostics, regenerative and frontier interventions under stricter conditions, and research or not-currently-offered categories that are tracked but never presented as routine. Reading it as a shopping list is the one misreading this page exists to prevent.
The base of the path is deliberately conventional. The foundational diagnostics and the first interventions — the bloodwork, the cardiometabolic and lifestyle work, the deficiency corrections — are standard, evidence-established medicine, and there is no secret in them; they are shown in truncated form precisely because they are common ground, not proprietary. The advanced layer begins where standard care stops: higher-resolution measurement and more complex intervention, optional, selective, and never automatic.
Advanced diagnostics are shown as category families, each holding a set of possible domains — generalized, not a list of named tests — that a clinician selects from when a specific picture warrants it:
Interventions are likewise mapped as families, each with its own domains, ascending from the entirely conventional to the genuinely frontier — and most of the weight sits at the conventional end:
Before any advanced regenerative, cellular, molecular or gene-related intervention, the path passes through a single explicit decision point. The Frontier Gate asks one question: is this person clinically, legally, ethically and operationally eligible for this category of intervention? It will not open without the full set of inputs — completed intake, baseline diagnostics, a risk-triage classification, the relevant advanced diagnostics, medication and contraindication review, an evidence- and regulatory-status review, physician approval, patient consent, and a monitoring plan. Its outcomes are equally explicit: eligible for the selected intervention; eligible only after further diagnostics; eligible only after stabilization or foundational work first; not eligible; refer to a specialist or external partner; research or future-tracking only; or do not offer. The gate is the difference between a clinic that maps the frontier responsibly and one that sells it; everything past this point is conditional on passing through it.
What keeps the whole layer a map rather than a sales sheet is that every category carries its true status, openly. The Honest Labels tag each diagnostic and intervention on four axes: evidence status (established / clinically plausible / emerging / experimental / research-only / not supported), regulatory status (available in clinic / via partner / referral only / research only / not available / jurisdiction-dependent), risk tier (low / moderate / high / requires review), and operational status (offered now / planned / future / research watchlist / not offered). A category being on the map says nothing about it being available, proven, or advisable — the labels say that, and they are not hidden in the small print.
Running horizontally across the whole path — diagnostics, planning, interventions, follow-up — is a continuous intelligence layer whose only job is to find, prioritize and reduce the major modifiable drivers of death, disease, frailty and accelerated aging. It is not a test or a product; it is a lens, and it reads across a wide set of risk domains: cardiovascular, metabolic, cancer-screening status, frailty and sarcopenia and fall risk, cognitive-decline risk, liver and kidney risk, inflammatory burden, sleep and autonomic risk, medication and polypharmacy risk, lifestyle and behavioral risk, family-history and genetic risk, and social and environmental factors. Its outputs are a prioritized risk summary, a modifiable-risk map, an intervention-priority sequence, a monitoring plan, and periodic reassessment — keeping the advanced layer pointed at what actually shortens lives, rather than at whatever is most novel.
The other horizontal layer is the wearable and continuous-monitoring stream that turns the plan from a fixed prescription into a tracked, adjusted one. It captures real-world, longitudinal physiology and behavior — resting heart rate, heart-rate variability, sleep duration, quality and regularity, activity and exercise tolerance, recovery, blood pressure, glucose variability, body composition, oxygen saturation, symptom trends — rather than one-time snapshots. Its uses run the length of the path: a pre-intervention baseline, safety monitoring, response and recovery tracking, protocol adjustment, adherence, and early-warning signals that surface change early enough to act on.
Behind the patient-facing map sits one more discipline worth naming: the clinic keeps an internal registry of diagnostics and interventions that are not yet part of the core pathway but may become relevant — sorted as active offering, available through a partner, under evaluation, research watchlist, future opportunity, or not offered on safety, regulatory or evidence grounds. It is an operational tool, not a menu; its point is that the frontier is tracked deliberately, with each item carrying its rationale, evidence and regulatory status and a clear decision — so nothing drifts into use without having passed the same honest test as everything else.
No. It is a map of category families, each with possible domains, an explicit gate, and honest status labels. Presence on the map says nothing about availability or proof — the labels say that, and most frontier categories are gated, referral-only, or not offered.
Because they are real fields, and an honest map of the advanced layer includes them — named as categories, gated, and labelled by evidence and regulation. Showing them responsibly is the opposite of promising them.
A full set of inputs — intake, baseline and advanced diagnostics, risk triage, medication and contraindication review, evidence and regulatory status, physician approval, consent and a monitoring plan — and it returns an explicit outcome, up to and including "not eligible" or "do not offer".
On the clinical path page. The base is conventional, evidence-established medicine, shown in truncated form; this page is only the advanced tier that sits beyond it.
This page describes a model and a map of a field, not a clinical service or an offer. Nothing here is medical advice, a diagnosis, a recommendation, or for sale; categories shown are not represented as available, proven, or advisable, and several are research-only or not offered. Advanced interventions are considered only after clinical review, eligibility gating, and compliance review. Anyone with a health concern should consult a qualified professional.
Related: the clinical path (base), the Virtual Longevity Clinic, biomarker-stratified care, the frontier, and the 6P framework.